A partially randomized patient-preference design showed intervention receipt, not preference congruence, drove improvements in fatigue, sleep, and pain interference among distressed post-treatment ...

Paxalisib blocks the PI3K/mTOR pathway, which plays a role in cancer cell growth and survival, but researchers have also ...

The omnipresence of pink during awareness campaigns can function as an involuntary cue for trauma recall, reactivating uncertainty, grief, and embodied memories tied to cancer care. Survivorship is ...

FDA cleared BRAVNETSA for adult SSTR+ GEP-NETs spanning foregut, midgut, and hindgut sites, adding a second approved lutetium ...

Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data. The investigational drug, first developed for brain cancer, is being ...

Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data.

After facing multiple cancers and hospice care, April Floyd credits her service dog Onyx with helping her find comfort, strength and hope. Years before Onyx entered my life, I lost my beloved dog ...

For years, much of cancer research has focused on understanding the tumor itself — how cancer cells grow, what causes them to change and how those cells can be targeted with treatment. But researchers ...

Cancer care complexity arises from multiple disease subtypes, expanding therapeutic sequences, and individualized constraints from comorbidities, concurrent medications, and drug–drug interactions.

FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast ...

After having cancer, travelling can become more than a getaway. It can be part of your emotional recovery. Rest, joy, and ...

Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung ...